Three critical findings from the ASCERTAIN V clinical trial offer important takeaways for older patients with acute myeloid leukemia and their care teams. First, the new oral combination therapy—decitabine-cedazuridine with venetoclax—demonstrates equivalent effectiveness to standard intravenous treatments currently considered the clinical standard. Second, this advancement eliminates the requirement for monthly hospital visits, allowing patients to manage treatment from home while maintaining therapeutic benefit.
Third, this therapy was specifically designed for elderly patients who typically struggle with intensive treatment regimens due to comorbidities, reduced tolerance for chemotherapy toxicity, or logistical barriers to frequent medical center access. For older adults with AML, this represents a meaningful shift toward treatment approaches that balance clinical efficacy with practical feasibility and quality of life considerations. Patients should discuss with their oncology teams whether they may be candidates for this emerging therapeutic option as it becomes more widely available following FDA review.
Read the full article on GMJ Newsroom.
Was this article helpful?
